PL2751092T3 - Selektywne i odwracalne inhibitory proteazy 7 specyficznej wobec ubikwityny - Google Patents

Selektywne i odwracalne inhibitory proteazy 7 specyficznej wobec ubikwityny

Info

Publication number: PL2751092T3
Authority: PL; Poland
Prior art keywords: selective; specific protease; reversible inhibitors; ubiquitin specific; ubiquitin
Prior art date: 2011-09-02

Application number

PL12751080T

Other languages

English (en)

Inventor

Frédéric Colland

Marie-Edith Gourdel

Original Assignee

Hybrigenics S.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-09-02

Filing date

2012-08-29

Publication date

2017-01-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46750347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2751092(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-08-29 Application filed by Hybrigenics S.A. filed Critical Hybrigenics S.A.

2017-01-31 Publication of PL2751092T3 publication Critical patent/PL2751092T3/pl

Links

102000018390 Ubiquitin-Specific Proteases Human genes 0.000 title 1
108010066496 Ubiquitin-Specific Proteases Proteins 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
230000002441 reversible effect Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Virology (AREA)
Oncology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Immunology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Hematology (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Psychology (AREA)
Biotechnology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

PL12751080T 2011-09-02 2012-08-29 Selektywne i odwracalne inhibitory proteazy 7 specyficznej wobec ubikwityny PL2751092T3 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP11306096A EP2565186A1 (en)	2011-09-02	2011-09-02	Selective and reversible inhibitors of ubiquitin specific protease 7

Publications (1)

Publication Number	Publication Date
PL2751092T3 true PL2751092T3 (pl)	2017-01-31

Family

ID=46750347

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL12751080T PL2751092T3 (pl)	2011-09-02	2012-08-29	Selektywne i odwracalne inhibitory proteazy 7 specyficznej wobec ubikwityny

Country Status (24)

Country	Link
US (1)	US9546150B2 (pl)
EP (2)	EP2565186A1 (pl)
JP (1)	JP6059228B2 (pl)
KR (1)	KR20140085430A (pl)
CN (1)	CN103930415B (pl)
AR (1)	AR087757A1 (pl)
AU (1)	AU2012300944B2 (pl)
BR (1)	BR112014004649A2 (pl)
CA (1)	CA2847017A1 (pl)
CL (1)	CL2014000511A1 (pl)
DK (1)	DK2751092T3 (pl)
ES (1)	ES2594603T3 (pl)
HU (1)	HUE029418T2 (pl)
IL (1)	IL231203A (pl)
LT (1)	LT2751092T (pl)
MA (1)	MA35361B1 (pl)
MX (1)	MX340500B (pl)
PL (1)	PL2751092T3 (pl)
PT (1)	PT2751092T (pl)
RU (1)	RU2622640C2 (pl)
SG (1)	SG11201400205QA (pl)
SI (1)	SI2751092T1 (pl)
TN (1)	TN2014000079A1 (pl)
WO (1)	WO2013030218A1 (pl)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2565186A1 (en) *	2011-09-02	2013-03-06	Hybrigenics S.A.	Selective and reversible inhibitors of ubiquitin specific protease 7
CA2896731A1 (en)	2012-12-28	2014-07-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof
CN105327350A (zh) *	2014-07-23	2016-02-17	中国科学院上海巴斯德研究所	泛素化途径相关因子在调控辅助性t细胞功能中的应用
MA41291A (fr)	2014-12-30	2017-11-07	Forma Therapeutics Inc	Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
AR103297A1 (es) *	2014-12-30	2017-05-03	Forma Therapeutics Inc	Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina
WO2016126935A1 (en) *	2015-02-05	2016-08-11	Forma Therapeutics, Inc.	Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
WO2016126926A1 (en)	2015-02-05	2016-08-11	Forma Therapeutics, Inc.	Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
US9932351B2 (en)	2015-02-05	2018-04-03	Forma Therapeutics, Inc.	Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
CN105251020B (zh) *	2015-09-29	2018-10-09	武汉大学	泛素特异性蛋白酶4（usp4）在治疗心肌肥厚中的功能及应用
GB201522267D0 (en) *	2015-12-17	2016-02-03	Mission Therapeutics Ltd	Novel compounds
GB201602854D0 (en)	2016-02-18	2016-04-06	Mission Therapeutics Ltd	Novel compounds
GB201604647D0 (en)	2016-03-18	2016-05-04	Mission Therapeutics Ltd	Novel compounds
GB201604638D0 (en)	2016-03-18	2016-05-04	Mission Therapeutics Ltd	Novel compounds
FR3052451B1 (fr) *	2016-06-10	2018-06-22	Les Laboratoires Servier	Nouveaux derives de piperidinyle hetero(aryl)-substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3061177B1 (fr) *	2016-12-28	2019-09-27	Les Laboratoires Servier	Nouveaux derives piperidinyles hetero(aryle)-substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
FR3052452B1 (fr)	2016-06-10	2018-06-22	Les Laboratoires Servier	Nouveaux derives de piperidinyle, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2017277732B2 (en) *	2016-06-10	2021-06-17	Les Laboratoires Servier	New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
WO2018009812A1 (en)	2016-07-08	2018-01-11	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer
GB201612938D0 (en) *	2016-07-26	2016-09-07	Almac Discovery Ltd	Pharmaceutical compounds
GB201616511D0 (en)	2016-09-29	2016-11-16	Mission Therapeutics Limited	Novel compounds
GB201616627D0 (en)	2016-09-30	2016-11-16	Mission Therapeutics Limited	Novel compounds
GB201617758D0 (en)	2016-10-20	2016-12-07	Almac Discovery Limited	Pharmaceutical compounds
EP3534964A4 (en) *	2016-11-03	2020-07-15	Trillium Therapeutics Inc.	IMPROVEMENT OF CD47 BLOCKING THERAPY BY PROTEASOME INHIBITORS
GB201708652D0 (en)	2017-05-31	2017-07-12	Mission Therapeutics Ltd	Novel compounds and uses
EP3642196B1 (en)	2017-06-20	2022-08-17	Mission Therapeutics Limited	Substituted cyanopyrrolidines with activity as dub inhibitors
AU2018342089B2 (en) *	2017-09-26	2024-07-11	Dana-Farber Cancer Institute, Inc.	Novel USP7 inhibitors for treating multiple myeloma
GB201801562D0 (en)	2018-01-31	2018-03-14	Almac Diagnostics Ltd	Pharmaceutical compounds
US12539292B2 (en)	2018-04-01	2026-02-03	Arvinas Operations, Inc.	BRM targeting compounds and associated methods of use
CA3113547A1 (en) *	2018-10-22	2020-04-30	Dana-Farber Cancer Institute, Inc.	Usp7 inhibition
JP2022512128A (ja) *	2018-12-06	2022-02-02	アルマック・ディスカバリー・リミテッド	医薬化合物およびユビキチン特異的プロテアーゼ１９（ｕｓｐ１９）阻害剤としてのその使用
EP3923987A1 (en)	2019-02-14	2021-12-22	Institut National de la Santé et de la Recherche Médicale (INSERM)	Use of usp7 inhibitors for the treatment of acute myeloid leukemia (aml)
GB201905371D0 (en)	2019-04-16	2019-05-29	Mission Therapeutics Ltd	Novel compounds
GB201905375D0 (en)	2019-04-16	2019-05-29	Mission Therapeutics Ltd	Novel compounds
MX2022000306A (es) *	2019-07-15	2022-03-11	Oncoarendi Therapeutics Sa	Amino triazoles sustituidos utiles como inhibidores de quitinasa.
GB201912674D0 (en)	2019-09-04	2019-10-16	Mission Therapeutics Ltd	Novel compounds
CN113087718B (zh) *	2020-01-09	2024-02-09	四川科伦博泰生物医药股份有限公司	噻吩并嘧啶酮类化合物及其医药应用
GB202001980D0 (en)	2020-02-13	2020-04-01	Almac Discovery Ltd	Therapeutic mentods
US20230087388A1 (en) *	2020-02-28	2023-03-23	Immunologik Gmbh	Inhibitors of human deubiquitinases for the treatment of coronaviral infections
AU2021253617A1 (en)	2020-04-08	2022-12-01	Mission Therapeutics Limited	N-cyanopyrrolidines with activity as USP30 inhibitors
EP4157332A4 (en) *	2020-05-26	2024-06-05	Lowell Therapeutics, Inc.	METHODS OF TREATING VIRAL INFECTION USING PROTEASE INHIBITORS
CN115667252A (zh)	2020-05-28	2023-01-31	特殊治疗有限公司	用于治疗线粒体功能障碍的作为usp30抑制剂的n-(1-氰基-吡咯烷-3-基)-5-(3-(三氟甲基)苯基)噁唑-2-甲酰胺衍生物和对应噁二唑衍生物
AU2021285130A1 (en)	2020-06-04	2023-01-19	Mission Therapeutics Limited	N-cyanopyrrolidines with activity as USP30 inhibitors
ES3040433T3 (en)	2020-06-08	2025-10-30	Mission Therapeutics Ltd	1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyrrole-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis
CN112047933B (zh) *	2020-10-15	2022-06-14	郑州大学	喹唑啉酮类usp7抑制剂及其制备方法和应用
GB202016800D0 (en)	2020-10-22	2020-12-09	Mission Therapeutics Ltd	Novel compounds
WO2023099561A1 (en)	2021-12-01	2023-06-08	Mission Therapeutics Limited	Substituted n-cyanopyrrolidines with activity as usp30 inhibitors
GB202200753D0 (en)	2022-01-21	2022-03-09	Almac Discovery Ltd	Pharmaceutical compounds
GB202408928D0 (en)	2024-06-21	2024-08-07	Mission Therapeutics Ltd	Novel compounds
WO2026015548A1 (en) *	2024-07-08	2026-01-15	Convelo Therapeutics, Inc.	Cyp51 inhibitors and method of using same
GB202411060D0 (en)	2024-07-29	2024-09-11	Mission Therapeutics Ltd	Novel compounds

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2796417A (en) *	1952-04-03	1957-06-18	American Cyanamid Co	Quinazolone compounds and methods of making the same
US3073826A (en) *	1960-10-20	1963-01-15	Mead Johnson & Co	3-pyrrolidylmethyl-4-quinazolones
WO1993012795A1 (en) *	1985-08-30	1993-07-08	Glazer Edward A	Quinazolin-4(3h)-one derivatives as anticoccidial agents
FI95572C (fi)	1987-06-22	1996-02-26	Eisai Co Ltd	Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US7842522B2 (en)	2001-10-19	2010-11-30	Applied Nanotech Holdings, Inc.	Well formation
US7569578B2 (en) *	2003-12-05	2009-08-04	Bristol-Meyers Squibb Company	Heterocyclic anti-migraine agents
SE0303280D0 (sv)	2003-12-05	2003-12-05	Astrazeneca Ab	Novel compounds
DK1737831T3 (da) *	2004-04-02	2013-08-19	Prana Biotechnology Ltd	Neurologisk aktive forbindelser
SE0401656D0 (sv)	2004-06-24	2004-06-24	Astrazeneca Ab	Chemical compounds
WO2006012577A2 (en) *	2004-07-22	2006-02-02	Bayer Pharmaceuticals Corporation	Quinazolinone derivatives useful for the regulation of glucose homeostasis and food intake
MX2007002434A (es) *	2004-08-31	2007-05-04	Astrazeneca Ab	Derivados de quinazolinona y su uso como inhibidores de b-raf.
WO2006072048A2 (en)	2004-12-30	2006-07-06	The Trustees Of Princeton University	Compositions and methods for identifying modulators of hausp
US7709516B2 (en)	2005-06-17	2010-05-04	Endorecherche, Inc.	Helix 12 directed non-steroidal antiandrogens
EP1749822B1 (en)	2005-08-05	2008-10-15	Hybrigenics S.A.	Novel cysteine protease inhibitors and their therapeutic applications
JP2009507022A (ja)	2005-09-06	2009-02-19	スミスクラインビーチャムコーポレーション	ベンズイミダゾールチオフェン類の位置選択的調製方法
AU2007262670B2 (en) *	2006-06-22	2012-12-20	Prana Biotechnology Limited	Method of treatment of glioma brain tumour
US20080188498A1 (en) *	2007-02-05	2008-08-07	Radix Pharmaceuticals, Inc.	Pyridopyrimidinone compounds with antimalarial activity
US9284297B2 (en)	2008-08-11	2016-03-15	President And Fellows Of Harvard College	Halofuginone analogs for inhibition of tRNA synthetases and uses thereof
WO2010051245A1 (en)	2008-11-03	2010-05-06	Merck Sharp & Dohme Corp.	Benzimidazole and aza-benzimidazole carboxamides
US20110177105A1 (en)	2010-01-15	2011-07-21	Roman Lopez	Novel Selective Inhibitors of Ubiquitin Specific Protease 7, the Pharmaceutical Compositions Thereof and Their Therapeutic Applications
EP2565186A1 (en) *	2011-09-02	2013-03-06	Hybrigenics S.A.	Selective and reversible inhibitors of ubiquitin specific protease 7

2011
- 2011-09-02 EP EP11306096A patent/EP2565186A1/en not_active Withdrawn
2012
- 2012-08-29 JP JP2014527641A patent/JP6059228B2/ja not_active Expired - Fee Related
- 2012-08-29 WO PCT/EP2012/066741 patent/WO2013030218A1/en not_active Ceased
- 2012-08-29 DK DK12751080.8T patent/DK2751092T3/en active
- 2012-08-29 KR KR1020147007456A patent/KR20140085430A/ko not_active Ceased
- 2012-08-29 MX MX2014002489A patent/MX340500B/es active IP Right Grant
- 2012-08-29 US US14/241,923 patent/US9546150B2/en not_active Expired - Fee Related
- 2012-08-29 LT LTEP12751080.8T patent/LT2751092T/lt unknown
- 2012-08-29 SG SG11201400205QA patent/SG11201400205QA/en unknown
- 2012-08-29 SI SI201230714A patent/SI2751092T1/sl unknown
- 2012-08-29 EP EP12751080.8A patent/EP2751092B1/en active Active
- 2012-08-29 BR BR112014004649A patent/BR112014004649A2/pt not_active Application Discontinuation
- 2012-08-29 ES ES12751080.8T patent/ES2594603T3/es active Active
- 2012-08-29 RU RU2014112692A patent/RU2622640C2/ru not_active IP Right Cessation
- 2012-08-29 PL PL12751080T patent/PL2751092T3/pl unknown
- 2012-08-29 CA CA2847017A patent/CA2847017A1/en not_active Abandoned
- 2012-08-29 PT PT127510808T patent/PT2751092T/pt unknown
- 2012-08-29 CN CN201280054148.2A patent/CN103930415B/zh not_active Expired - Fee Related
- 2012-08-29 AU AU2012300944A patent/AU2012300944B2/en not_active Ceased
- 2012-08-29 HU HUE12751080A patent/HUE029418T2/en unknown
- 2012-08-31 AR ARP120103228A patent/AR087757A1/es not_active Application Discontinuation
2014
- 2014-02-21 TN TNP2014000079A patent/TN2014000079A1/en unknown
- 2014-02-25 MA MA36781A patent/MA35361B1/fr unknown
- 2014-02-27 IL IL231203A patent/IL231203A/en active IP Right Grant
- 2014-02-28 CL CL2014000511A patent/CL2014000511A1/es unknown

Also Published As

Publication number	Publication date
HUE029418T2 (en)	2017-02-28
AR087757A1 (es)	2014-04-16
SI2751092T1 (sl)	2016-10-28
BR112014004649A2 (pt)	2017-03-14
AU2012300944B2 (en)	2017-06-01
PT2751092T (pt)	2016-11-04
EP2751092B1 (en)	2016-07-27
RU2014112692A (ru)	2015-10-10
LT2751092T (lt)	2016-10-25
JP2014527064A (ja)	2014-10-09
SG11201400205QA (en)	2014-03-28
MX2014002489A (es)	2014-11-14
EP2565186A1 (en)	2013-03-06
KR20140085430A (ko)	2014-07-07
TN2014000079A1 (en)	2015-07-01
US9546150B2 (en)	2017-01-17
CA2847017A1 (en)	2013-03-07
RU2622640C2 (ru)	2017-06-19
CN103930415B (zh)	2017-05-24
EP2751092A1 (en)	2014-07-09
IL231203A (en)	2017-04-30
MA35361B1 (fr)	2014-08-01
WO2013030218A4 (en)	2013-04-25
IL231203A0 (en)	2014-04-30
NZ621827A (en)	2016-07-29
US20140371247A1 (en)	2014-12-18
CL2014000511A1 (es)	2014-12-05
MX340500B (es)	2016-07-11
AU2012300944A1 (en)	2014-03-20
ES2594603T3 (es)	2016-12-21
CN103930415A (zh)	2014-07-16
DK2751092T3 (en)	2016-10-10
WO2013030218A1 (en)	2013-03-07
JP6059228B2 (ja)	2017-01-11

Publication	Publication Date	Title
SG11201400205QA (en)	2014-03-28	Selective and reversible inhibitors of ubiquitin specific protease 7
GB201103526D0 (en)	2011-04-13	Selective glycosidase inhibitors and uses thereof
PL2523938T3 (pl)	2015-02-27	Pochodne aminoakrydyny przydatne jako selektywne inhibitory proteazy 7 specyficznej dla ubikwityny
EP2678018A4 (en)	2015-09-30	COMBINATION OF CHINESE HEMMER AND USES THEREOF
IL230917A (en)	2017-02-28	1dyrk inhibitors and their uses
EP2663312A4 (en)	2014-10-22	IRAQ INHIBITORS AND THEIR USE
ZA201307499B (en)	2015-09-30	Compositions and methods comprising serine protease variants
PL3329919T3 (pl)	2020-05-18	Inhibitory ACC i ich zastosowania
ZA201305531B (en)	2014-10-29	Selective glycosidase inhibitors and uses thereof
HUE053325T2 (hu)	2021-06-28	Plazminogén aktivátor-1 gátlók és ezek alkalmazási eljárásai
ZA201304937B (en)	2014-03-26	Plasminogen and plasmin variants
IL231270A0 (en)	2014-04-30	Inhibitors of monooxygenase - 3 - kynurenine, pharmaceutical compositions, and methods of their use
IL230821A0 (en)	2014-03-31	Variants of plasminogen and plasmin
ZA201307956B (en)	2015-01-28	Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
IL230705A0 (en)	2014-03-31	Certain inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use
ZA201301795B (en)	2014-05-28	Inhibitors of notum pectinacetylesterase and methods of their use
EP2697246A4 (en)	2015-01-07	CYSTEINE PROTEASE SELECTIVE INHIBITORS AND USES THEREOF
SG10201601023UA (en)	2016-03-30	Inhibitors of nedd8-activating enzyme
SI2655388T1 (sl)	2016-10-28	Selektivni inhibitorji glikozidaze
GB201409877D0 (en)	2014-07-16	Composition pharmaceutical composition of protease inhibitors and production thereof
GB201010084D0 (en)	2010-07-21	Cysteine protease inhibitors
HK1192727A (en)	2014-08-29	Combination of kanase inhibitors and uses thereof
GB201120378D0 (en)	2012-01-11	Cysteine protease inhibitor salt
GB201120387D0 (en)	2012-01-11	Cysteine protease inhibitor salt
AU2011900234A0 (en)	2011-02-10	Serine protease inhibitors